Insight Molecular Diagnostics (IMDX) Stock Research

Insight Molecular Diagnostics

· IMDX

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

110.608 M

+6.21%

Over a week ago

Insight Molecular Diagnostics initiated with bullish view at Lucid Capital, here's why

IMDX

Aug 24, 6:11 AM

Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)

IMDX

Aug 10, 4:40 PM

Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay

IMDX

Jul 23, 9:28 AM

Insight Molecular Diagnostics submits GraftAssureDx for FDA review

IMDX

Mar 26, 4:45 PM

Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year

IMDX

Mar 26, 4:44 PM

Insight Molecular Diagnostics highlights publication of study on GraftAssure

IMDX

Mar 13, 8:07 AM

Insight Molecular Diagnostics completes milestones advancing GraftAssureDx

IMDX

Mar 3, 8:10 AM

Insight Molecular Diagnostics price target raised by $4 at Lake Street, here's why

IMDX

Feb 17, 8:48 AM

Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering

IMDX

Feb 11, 8:16 AM

Insight 'congratulated' STAR working group on organ health testing paper

IMDX

Jan 13, 9:06 AM

Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs

IMDX

Jan 6, 8:02 AM

iMDx prepares for U.S. commercial launch of GraftAssureDx

IMDX

Jan 5, 7:06 AM

Fourteen new option listings on November 12th

Nov 12, 8:30 AM

Insight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year

IMDX

Nov 10, 5:07 PM

Insight Molecular says kidney transplant patient achieved 'immune reset'

IMDX

Oct 6, 7:34 AM

No more stories

Charts